BOSTON--(BUSINESS WIRE)--Mar. 1, 2017--
Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is
developing innovative and proprietary treatments for cramps and spasms
associated with the severe neurological diseases of ALS, MS and
peripheral neuropathies such as Charcot-Marie-Tooth (CMT), announced
today that it will report its financial results for the fourth quarter
and year ended December 31, 2016 on Wednesday, March 8, 2017 before the
U.S. financial markets open. The Company will host a conference call and
webcast at 8:30 a.m. ET to discuss fourth quarter and fully year 2016
financial results and provide a business update. Individuals interested
in participating in the call should dial (855) 780-7202 (U.S. and
Canada) or (631) 485-4874 (International).
A live webcast may be accessed in the Investors section of the Company's
website at www.flex-pharma.com.
Please log on to the Flex Pharma website approximately 15 minutes prior
to the scheduled webcast to ensure adequate time for any software
downloads that may be required. A replay of the webcast will be
available on Flex Pharma's website for three months.
About Flex Pharma
Flex Pharma, Inc. is a biotechnology company that is developing
innovative and proprietary treatments for cramps and spasms associated
with the severe neurological diseases of ALS, MS and peripheral
neuropathies such as Charcot-Marie-Tooth (CMT). Flex Pharma was founded
by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel
Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of
ion channels and neurobiology, along with Chair and CEO Christoph
Westphal, M.D., Ph.D.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170301006441/en/
Source: Flex Pharma, Inc.
Flex Pharma, Inc.
Elizabeth Woo, 617-874-1829
Relations & Corporate Communications